文献速递产科母胎医学

依诺肝素预防有相关病史女性子痫前期和宫内生长受限的随机试验

Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial.
PubMed 文献 · Am J Obstet Gynecol · 2017-01-30

这项在3国5个三级中心开展的非盲随机对照试验,纳入有子痫前期和/或小于胎龄儿病史的单胎妊娠女性,比较标准高危护理加依诺肝素40 mg每日皮下注射与单纯标准高危护理。结果显示,加用依诺肝素未降低子痫前期和/或小于胎龄儿(<5th定制出生体重百分位)的发生率:18/72(25%)vs 17/77(22.1%),OR 1.19(95%CI 0.53-2.64),次要结局及血清抗血管生成因子水平亦无差异。

要点

  • 有子痫前期和/或小于胎龄儿病史者,加用依诺肝素未降低复发风险。
  • 主要结局发生率:依诺肝素组25% vs 无依诺肝素组22.1%,OR 1.19(95%CI 0.53-2.64)。
  • 子痫前期患者sFlt-1和sEng升高,但依诺肝素未改变这些因子水平。

核心结论

  • 在标准高危护理基础上加用依诺肝素,不能降低有子痫前期和小于胎龄儿病史女性下次妊娠的复发风险。

研究设计与样本

  • 非盲随机对照试验,在3个国家的5个三级护理中心开展。
  • 纳入孕>6+0至<16+0周、根据产科病史判定为子痫前期和/或小于胎龄儿高风险的 viable 单胎妊娠女性。
  • 按1:1随机分配至标准高危护理或标准高危护理加依诺肝素40 mg(4000 IU)每日皮下注射,从入组至36+0周或分娩(以较早者为准)。
  • 标准高危护理定义为高危产前门诊服务协调的护理、阿司匹林100 mg每日至36+0周,以及既往子痫前期者钙1000-1500 mg每日至36+0周。
  • 共156例入组并纳入分析,149例纳入结局分析(依诺肝素组72例,标准高危护理组77例),排除7例<16周流产者;主要分析基于意向性治疗。

主要发现

  • 主要结局(子痫前期和/或小于胎龄儿<5th定制出生体重百分位的复合结局):依诺肝素组18/72(25%)vs 无依诺肝素组17/77(22.1%),OR 1.19(95%CI 0.53-2.64)。
  • 任何次要结局指标均无差异。
  • 发生子痫前期者sFlt-1和sEng水平升高,但依诺肝素组与单纯标准高危护理组之间这些抗血管生成因子(及其他所测血清分析物)水平无差异。
  • 大多数参与者(151/156,97%)接受了阿司匹林。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia and small-for-gestational-age pregnancy are major causes of maternal and perinatal morbidity and mortality. Women with a previous pregnancy affected by these conditions are at an increased risk of recurrence in a future pregnancy. Past trials evaluating the effect of low-molecular-weight heparin for the prevention of recurrence of preeclampsia and small-for-gestational-age pregnancy have shown conflicting results with high levels of heterogeneity displayed when trials were compared. OBJECTIVE: We sought to assess the effectiveness of enoxaparin in addition to high-risk care for the prevention of preeclampsia and small-for-gestational-age pregnancy in women with a history of these conditions. STUDY DESIGN: This was an open-label randomized controlled trial in 5 tertiary care centers in 3 countries. Women with a viable singleton pregnancy were invited to participate between >6+0 and <16+0 weeks if deemed to be at high risk of preeclampsia and/or small for gestational age based on their obstetric history. Eligible participants were randomly assigned in a 1-to-1 ratio to standard high-risk care or standard high-risk care plus enoxaparin 40 mg (4000 IU) by subcutaneous injection daily from recruitment until 36+0 weeks or delivery, whichever occurred sooner. Standard high-risk care was defined as care coordinated by a high-risk antenatal clinic service, aspirin 100 mg daily until 36+0 weeks, and-for women with prior preeclampsia-calcium 1000-1500 mg daily until 36+0 weeks. In a subgroup of participants serum samples were taken at recruitment and at 20 and 30 weeks' gestation and later analyzed for soluble fms-like tyrosine kinase-1, soluble endoglin, endothelin-1, placental growth factor, and soluble vascular cell adhesion molecule 1. The primary outcome was a composite of preeclampsia and/or small-for-gestational-age <5th customized birthweight percentile. All data were analyzed on an intention-to-treat basis. The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12609000699268). RESULTS: Between July 26, 2010, and Oct. 28, 2015, a total of 156 participants were enrolled and included in the analysis. In all, 149 participants were included in the outcome analysis (72 receiving standard high-risk care plus enoxaparin and 77 receiving standard high-risk care only). Seven women who miscarried <16 weeks' gestation were excluded. The majority of participants (151/156, 97%) received aspirin. The addition of enoxaparin had no effect on the rate of preeclampsia and/or small-for-gestational-age <5th customized birthweight percentile: enoxaparin 18/72 (25%) vs no enoxaparin 17/77 (22.1%) (odds ratio, 1.19; 95% confidence interval, 0.53-2.64). There was also no difference in any of the secondary outcome measures. Levels of soluble fms-like tyrosine kinase-1 and soluble endoglin increased among those who developed preeclampsia, but there was no difference in levels of these antiangiogenic factors (nor any of the other serum analytes measured) among those treated with enoxaparin compared to those receiving standard high-risk care only. CONCLUSION: The use of enoxaparin in addition to standard high-risk care does not reduce the risk of recurrence of preeclampsia and small-for-gestational-age infants in a subsequent pregnancy.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol. 2017. PMID: 28153659. doi:10.1016/j.ajog.2017.01.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。